Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PPCB Propanc Biopharma, Inc.

休市中 08-14 16:00:00 EDT

1.22

+0.00

0.00%

盘后1.22

+0.000.00%

19:59 EDT

最高1.29	最低1.20	成交量3.95万
今开1.21	昨收1.22	日振幅7.38%
总市值277.96万	流通市值152.51万	总股本227.84万
成交额4.85万	换手率3.16%	流通股本125.01万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":1.22,"timestamp":1786737600000,"preClose":1.22,"halted":0,"volume":39528,"hourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.22,"latestTime":"19:59 EDT","volume":226,"amount":276.088,"timestamp":1786751970523,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":1250069,"shares":2278372,"eps":-32.455997,"marketStatus":"休市中","change":0,"latestTime":"08-14 16:00:00 EDT","open":1.21,"high":1.29,"low":1.2,"amount":48455.133962399996,"amplitude":0.07377,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-32.455997,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":1.22,"preHourTrading":{"tag":"盘前","latestPrice":1.2002,"preClose":1.22,"latestTime":"09:05 EDT","volume":2323,"amount":2796.1377219,"timestamp":1786712719252,"change":-0.0198,"changeRate":-0.01623,"amplitude":0.050574},"postHourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.22,"latestTime":"19:59 EDT","volume":226,"amount":276.088,"timestamp":1786751970523,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5007966857179837},"requestUrl":"/m/hq/s/PPCB/wiki","defaultTab":"wiki","newsList":[{"id":"1159793711","title":"Propanc Biopharma宣布PRP在胰腺导管腺癌模型中展现超90%肿瘤生长抑制及显著生存获益的积极临床前与早期转化数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159793711","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159793711?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:37","pubTimestamp":1786019874,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近日公布了其核心候选药物PRP的积极临床前和早期转化研究结果。在胰腺导管腺癌（PDAC）模型中，PRP显示出超过90%的肿瘤生长抑制率，并显著延长了实验对象的生存期。这一里程碑式的数据，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136433126","title":"Propanc Biopharma, Inc.将在澳大利亚提交CTA，启动针对30-40名晚期癌症患者的1B期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1136433126","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136433126?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:46","pubTimestamp":1779281202,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 计划在澳大利亚提交临床试验申请，旨在启动一项涉及30至40名晚期癌症患者的1B期研究。这一举措标志着该公司在推进其新型癌症治疗方案的临床开发道路上迈出了关键一步。在澳大利亚提交CTA的决定，反映了公司利用该国高效监管框架和强大临床研究生态系统的战略考量。成功完成此阶段研究，有望为Propanc Biopharma, Inc.的核心产品管线带来重要的价值提升，并为其针对难治性癌症的开发策略提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186690041","title":"Propanc Biopharma公司计划开展两项II期研究，针对胰腺癌和卵巢癌各招募60名患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1186690041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186690041?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:46","pubTimestamp":1779281199,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司宣布，将启动两项独立的II期临床研究，分别针对胰腺癌和卵巢癌患者。据悉，每项研究计划招募60名参与者，以评估其候选疗法的安全性与有效性。这一举措标志着该公司在推进其肿瘤治疗管线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158942593","title":"Propanc Biopharma实施并股计划，以维系纳斯达克上市地位并推进增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1158942593","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158942593?lang=zh_cn&edition=full","pubTime":"2026-05-14 10:00","pubTimestamp":1778724015,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已正式执行反向股票分割（并股）方案。此举旨在满足纳斯达克资本市场持续上市的最低股价要求，从而稳固其上市地位。同时，公司期望这一资本结构调整能为其既定的长期业务增长与拓展计划提供更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118487671","title":"Propanc Biopharma公司提交文件，计划由售股股东转售最多1500万股普通股——SEC备案披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118487671","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118487671?lang=zh_cn&edition=full","pubTime":"2026-04-11 05:33","pubTimestamp":1775856802,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已向美国证券交易委员会提交相关文件，内容涉及一项由售股股东发起的普通股转售计划。根据备案信息，该计划拟转售的普通股数量最高可达1500万股。\n此次提交标志着售股股东可能将在公开市场进行大规模股份出售。相关细节已在SEC备案中列明，市场将密切关注此举对公司股权结构及二级市场股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193342077","title":"Propanc Biopharma与西班牙哈恩大学及格拉纳达大学达成多年抗衰老与癌症研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1193342077","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193342077?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:46","pubTimestamp":1774356416,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC PINK: PPCB) 已正式启动与西班牙哈恩大学及格拉纳达大学的长期研究合作。该合作项目聚焦于抗衰老机制与癌症治疗领域的前沿探索，旨在通过多学科交叉研究推动新型生物医药解决方案的开发。此次合作将整合双方在生物医药领域的科研优势，共同探索潜在的新型疗法，为应对全球老龄化挑战及癌症治疗提供新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169122345","title":"Propanc Biopharma, Inc. 优先推进PRP临床开发，聚焦胰腺癌与卵巢癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1169122345","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169122345?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:07","pubTimestamp":1773320852,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 正全力推进其核心候选药物PRP的临床开发进程，并将胰腺癌与卵巢癌的治疗研究作为首要战略方向。公司致力于通过创新疗法应对这些高致死率癌症的临床挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142670016","title":"Propanc Biopharma公司PRP药物I B期首次人体试验定于2026年启动；1亿美元资金设施已就位","url":"https://stock-news.laohu8.com/highlight/detail?id=1142670016","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142670016?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:06","pubTimestamp":1773320789,"startTime":"0","endTime":"0","summary":"生物制药公司Propanc Biopharma Inc宣布，其主打候选药物PRP的I B期首次人体临床试验计划于2026年正式开展。该公司已确保一项高达1亿美元的资金支持，为临床试验的顺利推进提供了坚实的财务保障。\n此次I B期试验标志着PRP在研发进程中迈出关键一步，旨在评估该药物在人体中的安全性与初步疗效。充足的资金储备将助力公司高效执行临床开发计划，加速潜在疗法的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167918509","title":"Propanc Biopharma, Inc. 公布PRP在临床前胰腺癌模型中展示超过85%的肿瘤生长抑制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167918509","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167918509?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:06","pubTimestamp":1773320779,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近期宣布，其研发的主要候选药物PRP在针对胰腺癌的临床前研究中取得了显著成果。数据显示，PRP能够有效抑制肿瘤生长，抑制率超过85%。这一积极结果凸显了PRP在治疗胰腺癌方面的巨大潜力，为后续的临床开发提供了强有力的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192836728","title":"Propanc Biopharma与Fyonibio签署服务协议，为1B期首次人体研究建立并验证药代动力学分析方法","url":"https://stock-news.laohu8.com/highlight/detail?id=1192836728","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192836728?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:45","pubTimestamp":1773146712,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 已正式与Fyonibio达成一项服务协议，核心目标是为其即将开展的1B期首次人体临床研究，建立并验证一套关键的药代动力学分析方法。该协议的签署标志着公司在推进其领先候选药物研发进程中迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170463595","title":"Propanc Biopharma主力资产PRP在临床前胰腺癌模型中显示超过85%的肿瘤生长抑制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1170463595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170463595?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:48","pubTimestamp":1772545721,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC: PPCB) 宣布，其领先研发资产PRP在针对胰腺癌的临床前研究模型中，展现出超过85%的肿瘤生长抑制效果。这一积极数据进一步验证了PRP作为潜在抗癌疗法的有效性，特别是在治疗胰腺癌这一难治性癌症领域显示出巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.propanc.com","stockEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":-0.2515},{"period":"3month","weight":-0.2824},{"period":"6month","weight":-0.7709},{"period":"1year","weight":-0.9953},{"period":"ytd","weight":-0.9091}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Propanc Biopharma, Inc.最初于2007年10月15日在澳大利亚维多利亚州墨尔本成立。2010年11月23日，该公司在特拉华州重新注册并重新注册。他们是一家发展阶段的医疗保健公司，目前专注于为患有胰腺癌、卵巢癌和癌症的患者开发新的癌症治疗方法。利用他们的科学和肿瘤学顾问，他们开发了一种合理的抗癌化合物复合配方，这些化合物共同发挥多种作用，旨在控制或防止肿瘤在体内复发和扩散。他们的主要候选产品PRP是他们新配方的变体，涉及酶原，即酶的无活性前体。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.35863},{"month":2,"riseRate":0,"avgChangeRate":-0.3412},{"month":3,"riseRate":0,"avgChangeRate":-0.231595},{"month":4,"riseRate":0,"avgChangeRate":-0.393912},{"month":5,"riseRate":0.25,"avgChangeRate":-0.125956},{"month":6,"riseRate":0.5,"avgChangeRate":0.512759},{"month":7,"riseRate":0.2,"avgChangeRate":-0.081258},{"month":8,"riseRate":0.25,"avgChangeRate":-0.309688},{"month":9,"riseRate":0,"avgChangeRate":-0.414214},{"month":10,"riseRate":0,"avgChangeRate":-0.267792},{"month":11,"riseRate":0,"avgChangeRate":-0.325477},{"month":12,"riseRate":0.25,"avgChangeRate":-0.177784}],"exchange":"NASDAQ","name":"Propanc Biopharma, Inc.","nameEN":"Propanc Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Propanc Biopharma, Inc.(PPCB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Propanc Biopharma, Inc.,PPCB,Propanc Biopharma, Inc.股票,Propanc Biopharma, Inc.股票老虎,Propanc Biopharma, Inc.股票老虎国际,Propanc Biopharma, Inc.行情,Propanc Biopharma, Inc.股票行情,Propanc Biopharma, Inc.股价,Propanc Biopharma, Inc.股市,Propanc Biopharma, Inc.股票价格,Propanc Biopharma, Inc.股票交易,Propanc Biopharma, Inc.股票购买,Propanc Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Propanc Biopharma, Inc.(PPCB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}